HCPLive 5 Stories in Under 5: Week of 05/18
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
HCPLive 5 Stories in Under 5: Week of 05/18
-
ナレーター：
-
著者：
このコンテンツについて
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for May 12-18, 2025.
FDA Approves Once-Daily Roflumilast (ZORYVE) Foam 0.3% for Scalp and Body Psoriasis
The FDA approved once-daily roflumilast (Zoryve) foam 0.3% for treating plaque psoriasis on the scalp and body in patients aged 12 and older. This marks the fifth overall indication for roflumilast, adding to its existing approvals in psoriasis and atopic dermatitis.
FDA Warns About Rare, Severe Itching After Stopping Cetirizine or Levocetirizine
The FDA issued a warning about severe pruritus that can occur after stopping long-term cetirizine or levocetirizine use. Manufacturers will be required to add a label warning noting that symptoms may improve if the medications are restarted.
FDA Approves Susvimo for Treatment of Diabetic Retinopathy
The FDA approved Genentech’s Susvimo, a ranibizumab delivery system, as the first continuous refillable treatment for diabetic retinopathy. Susvimo offers sustained vision maintenance with refills needed only once every nine months.
Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study
The Essence study showed olezarsen significantly reduced triglyceride levels in patients with moderate hypertriglyceridemia at ASCVD risk. Monthly doses achieved about 60% reductions, with most patients reaching normal triglyceride levels after six months.
Ruxoprubart Shows Efficacy for PNH in Interim Phase 2 Trial Results
Interim Phase 2 results showed ruxoprubart met all primary efficacy endpoints in adults with paroxysmal nocturnal hemoglobinuria. The therapy led to transfusion avoidance, improved hemoglobin, reduced LDH, and increased PNH clone size at 12 weeks.